Prednisone 5Mg Tab

DRUG3 trials

Sponsors

Eye & ENT Hospital of Fudan University, DisperSol Technologies, LLC, University of British Columbia

Conditions

Prostate CancerSudden Hearing LossVestibular Vertigo

Phase 1

PK and Dose Escalation and Expansion Study of DST-2970

TerminatedNCT04291664

DisperSol Technologies, LLCProstate Cancer

Start: 2020-01-31End: 2023-01-27Updated: 2024-10-17

Phase 2

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

RecruitingNCT04812366

University of British ColumbiaProstate Cancer

Start: 2021-09-21End: 2027-06-01Target: 315Updated: 2026-08-14

Unknown Phase

Vestibular Prognosis Assessment of ISSNHL With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids

Eye & ENT Hospital of Fudan UniversitySudden Hearing Loss, Vestibular Vertigo

Start: 2019-07-31End: 2020-12-31Target: 72Updated: 2019-07-24

Related Papers

3D Structural Revelations of Neoadjuvant Hormonal Therapy Treatment in High Risk Localized Prostate Cancer by Light-Sheet Imaging.

Journal of Clinical Oncology2026-05-28

Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial.

2025-03-101 citations

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.

2025-03-074 citations

Genomic alterations and their pathologic responses in high-risk localized prostate cancer (HRLPC) in subprotocol 1 of the Genomic Umbrella Neoadjuvant study (GUNS).

Journal of Clinical Oncology2025-02-101 citations

Vestibular prognosis in idiopathic sudden sensorineural hearing loss with vestibular dysfunction treated with oral or intratympanic glucocorticoids: a protocol for randomized controlled trial.

2020-07-225 citations